Liquid biopsy detects 50+ cancer types with 91% accuracy via blood draws, NEJM November 3 trials.
Multi-cancer early detection 80% sensitivity stage I, 95% specificity Galleri test, advancing screening.
Florida Cancer Specialist’s test identifies circulating tumor cells in early-stage patients, October 2025.
DMMR solid cancers ctDNA screening 6-10 weeks post-surgery, pembrolizumab for residual disease, MSKCC phase II.
Half recurrences detected 6 months prior to imaging, ctDNA relapse 1 year before scans.
$7.05 billion market 2025, 14.9% CAGR to 2034, Polaris, $22.69 billion by 2034.
This biopsy’s quiet precision unveils new era where blood’s vast drops bridge tumor voids, transforming detection with enduring harmony.
